Drug Desensitization in 17-year-old Male with Mast Cell Activation Syndrome, Pneumonia, and Antibiotic Hypersensitivities

Overview

Journal AME Case Rep

Publisher AME Publishing Company

Specialty General Medicine

Date 2018 Sep 29

PMID 30263994

Citations 3

Authors

Patrick Staso

Andrey Leonov

Affiliations

Soon will be listed here.

Abstract

Rapid desensitization (RD) is utilized in order to provide necessary medications to patients with drug hypersensitivity. RD is performed in a closely monitored setting to protect patients from severe anaphylactic or anaphylactoid reactions. A recently classified syndrome, mast cell activation syndrome (MCAS), has been defined by episodic symptoms caused by mast cell mediators and is associated with specific laboratory markers. Patient with MCAS and history of systemic reactions to ceftriaxone and azithromycin presented with pneumonia requiring treatment with ceftriaxone and azithromycin, both provided via desensitization protocols. Desensitization for drug hypersensitivities in the setting of MCAS presents several controversial issues as mechanism of hypersensitivity may not be related to IgE-mediated but rather non-specific mast-cell degranulation. The controversies of diagnosis and management of antibiotic hypersensitivity in patients with MCAS discussed. Our case demonstrates that desensitization protocols can be used in MCAS patients with noted hypersensitivities. The intricacies of desensitization in the setting of MCAS are not fully understood and will require further research and characterization.

Citing Articles

The Role of Mast Cells in the Induction and Maintenance of Inflammation in Selected Skin Diseases.

Wozniak E, Owczarczyk-Saczonek A, Lange M, Czarny J, Wygonowska E, Placek W Int J Mol Sci. 2023; 24(8).

PMID: 37108184 PMC: 10139379. DOI: 10.3390/ijms24087021.

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS).

Spataro F, Viggiani F, Macchia D, Rollo V, Tummolo A, Suppressa P Orphanet J Rare Dis. 2022; 17(1):402.

PMID: 36329518 PMC: 9635105. DOI: 10.1186/s13023-022-02556-7.

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Gelincik A, Brockow K, Celik G, Dona I, Mayorga C, Romano A Allergy. 2020; 75(11):2775-2793.

PMID: 32511784 PMC: 7300843. DOI: 10.1111/all.14439.

References

Frieri M, Patel R, Celestin J . Mast cell activation syndrome: a review. Curr Allergy Asthma Rep. 2012; 13(1):27-32. DOI: 10.1007/s11882-012-0322-z. View

Frieri M . Mast Cell Activation Syndrome. Clin Rev Allergy Immunol. 2015; 54(3):353-365. DOI: 10.1007/s12016-015-8487-6. View

Khan D . Treating patients with multiple drug allergies. Ann Allergy Asthma Immunol. 2012; 110(1):2-6. DOI: 10.1016/j.anai.2012.11.002. View

Gupta M, Gomes J, Irizarry J, DaVeiga S . The use of standardized drug desensitization protocols at a pediatric institution. J Allergy Clin Immunol Pract. 2016; 5(3):834-836.e5. DOI: 10.1016/j.jaip.2016.11.012. View

Molderings G, Brettner S, Homann J, Afrin L . Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011; 4:10. PMC: 3069946. DOI: 10.1186/1756-8722-4-10. View

Hamilton M, Hornick J, Akin C, Castells M, Greenberger N . Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011; 128(1):147-152.e2. DOI: 10.1016/j.jaci.2011.04.037. View

Rerkpattanapipat T, Chiriac A, Demoly P . Drug provocation tests in hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2011; 11(4):299-304. DOI: 10.1097/ACI.0b013e328348a4e9. View

. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010; 105(4):259-273. DOI: 10.1016/j.anai.2010.08.002. View

Schnyder B . Approach to the patient with drug allergy. Immunol Allergy Clin North Am. 2009; 29(3):405-18. DOI: 10.1016/j.iac.2009.04.005. View

10.

Castells Guitart M . Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. J Investig Allergol Clin Immunol. 2014; 24(2):72-9. View

11.

Pichler W, Hausmann O . Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. Int Arch Allergy Immunol. 2016; 171(3-4):166-179. DOI: 10.1159/000453265. View

12.

Legere 3rd H, Palis R, Bouza T, Uluer A, Castells M . A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009; 8(6):418-24. PMC: 2787787. DOI: 10.1016/j.jcf.2009.08.002. View

13.

Akin C, Valent P, Metcalfe D . Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010; 126(6):1099-104.e4. PMC: 3753019. DOI: 10.1016/j.jaci.2010.08.035. View

14.

Farnam K, Chang C, Teuber S, Gershwin M . Nonallergic drug hypersensitivity reactions. Int Arch Allergy Immunol. 2012; 159(4):327-45. DOI: 10.1159/000339690. View

15.

Lieberman P, Garvey L . Mast Cells and Anaphylaxis. Curr Allergy Asthma Rep. 2016; 16(3):20. DOI: 10.1007/s11882-016-0598-5. View

16.

Castells M . A New Era for Drug Desensitizations. J Allergy Clin Immunol Pract. 2015; 3(4):639-40. DOI: 10.1016/j.jaip.2015.05.006. View

17.

Romano A, Torres M, Castells M, Sanz M, Blanca M . Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011; 127(3 Suppl):S67-73. DOI: 10.1016/j.jaci.2010.11.047. View

18.

Picard M, Giavina-Bianchi P, Mezzano V, Castells M . Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther. 2013; 35(5):548-62. DOI: 10.1016/j.clinthera.2013.04.001. View

19.

Torres M, Mayorga C, Blanca-Lopez N, Blanca M . Hypersensitivity reactions to beta-lactams. Exp Suppl. 2013; 104:165-84. DOI: 10.1007/978-3-0348-0726-5_11. View